BiomX Inc. (PHGE) Stock Score, Valuation & Financial Research

BiomX Inc. is in the Industrials sector and Aerospace & Defense industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PHGE

BiomX Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.85. These figures are a research snapshot, not a buy or sell recommendation.

What BiomX Inc. does

Operating as a holding company, BiomX Inc. is dedicated to advancing technologies within the realms of defense, security, and essential infrastructure. Its diverse array of offerings features specialized solutions like counter-unmanned aerial vehicle systems, intelligent AI-powered command-and-control, comprehensive border and perimeter protection, expansive surveillance capabilities, and aerial fire suppression tools. The firm caters to a broad spectrum of clients, encompassing national defense organizations, primary government contractors, transportation management entities, local municipalities, and key infrastructure operators. BiomX Inc. commenced operations in 2015 and maintains its principal office in Dover, Delaware.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

BiomX is a clinical-stage biotechnology company that does not currently have any products approved or available for sale. The company relies on capital raises, private placements, and potential future licensing or collaboration agreements to fund its research and development activities, as it has not yet generated revenue from product sales.

Products and services

  • The company is focused on the development of phage-based therapies, including its lead candidate BX011, a fixed multi-phage cocktail designed for the treatment of diabetic foot infections associated with Staphylococcus aureus.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to conduct clinical trials and preclinical studies. Source

Competitors and product-market comparisons

  • Adaptive Phage Therapeutics — A company focused on the development of phage-based therapies for bacterial infections. Source

Business strengths to evaluate

  • Proprietary phage-based technology platform Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Insolvency proceedings of Israeli subsidiary BiomX Ltd. Source
  • Dependence on additional financing to continue operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PHGE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.85
Market capitalization:
5M (currency not supplied)
Revenue:
USD 332K
Net income:
USD -45.42M
Free cash flow:
USD -26.39M
Cash:
USD 347K
Total debt:
USD 3.37M
EPS:
USD -200.60

What stands out

  • Free cash flow is USD -26.39M, negative for the stored period.
  • The balance sheet shows USD 347K of cash versus USD 3.37M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -7949.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Debt exceeds cash by USD 3.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PHGE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PHGE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is PHGE's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for PHGE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PHGE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research PHGE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.